Merck Sharp and Dohme announces UK launch of Zinplava

Merck Sharp and Dohme has announced the UK launch of Zinplava, a new treatment for the prevention of recurrence of C. difficile infections in adults deemed to be at high risk.

The bezlotoxumab therapy is administered as a single, one-off, one-hour intravenous infusion alongside standard-of-care antibiotic therapy, and represents the first non-antibiotic option for this indication to be licensed in Europe.

It is also the first therapy for C. difficile that targets the toxin that causes the disease, meaning it is able to reduce the risk of recurrence for at least three months compared to antibiotic therapy alone.

C. difficile is a type of bacteria that colonises the bowel and can lead to damage to the lining of the colon, potentially causing perforation of the colon, sepsis and death.

Dr Mike England, Merck Sharp and Dohme's interim medical director, said: "The launch of bezlotoxumab in the UK continues MSD's longstanding tradition of bringing forward novel therapies to address serious infectious diseases, and we are proud to add this important treatment to our existing portfolio of anti-infective medicines."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.